Literature DB >> 12426270

Significance of a plasma D-dimer test in patients with primary pulmonary hypertension.

David Shitrit1, Daniele Bendayan, Ariella Bar-Gil-Shitrit, Michael Huerta, Bernard Rudensky, Gershon Fink, Mordechai R Kramer.   

Abstract

BACKGROUND: D-dimer, a degradation product of fibrin, has been increasingly used as a marker or prognostic factor in various thrombotic diseases.
OBJECTIVE: To assess the significance of a d-dimer test in patients with primary pulmonary hypertension (PPH). PATIENTS AND METHODS: Fourteen patients with PPH (12 women and 2 men) aged 25 to 68 years (mean +/- SD age, 50 +/- 14 years) entered the study. Plasma d-dimer was determined by Miniquant assay (Biopool International; Venture, CA) 3 +/- 5 months after the disease onset, and patients were followed up for 1 year. We compared the d-dimer levels to the demographic, clinical, and hemodynamic data of the patients.
RESULTS: D-dimer levels were positively correlated with New York Heart Association classification (r = 0.59, p = 0.01) and pulmonary artery pressure (r = 0.43, p = 0.03) and were negatively correlated with oxygen saturation (r = - 0.45, p = 0.03) and 6-min walk distance (r = - 0.49, p = 0.04). One-year survival was also negatively correlated with d-dimer (point-biserial r = - 0.71, p = 0.004), with a higher d-dimer value associated with poorer survival. No significant correlations were found between d-dimer values and sex, age, diffusing capacity of the lung for carbon monoxide, or cardiac index.
CONCLUSION: D-dimer levels may have a role in the evaluation of patients with PPH. This simple, noninvasive test may be helpful for identifying patients who are at a higher risk for severe disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426270     DOI: 10.1378/chest.122.5.1674

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 2.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

3.  D-dimer level and the risk for thrombosis in systemic lupus erythematosus.

Authors:  Haifeng Wu; Daniel J Birmingham; Brad Rovin; Kevin V Hackshaw; Nabil Haddad; Douglas Haden; Chack-Yung Yu; Lee A Hebert
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

4.  Measurement of dyspnea in patients with obstructive sleep apnea.

Authors:  Kensaku Aihara; Toru Oga; Chikara Yoshimura; Takefumi Hitomi; Yuichi Chihara; Yuka Harada; Kimihiko Murase; Yoshiro Toyama; Kiminobu Tanizawa; Tomohiro Handa; Tomomasa Tsuboi; Michiaki Mishima; Kazuo Chin
Journal:  Sleep Breath       Date:  2012-08-03       Impact factor: 2.816

5.  Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study.

Authors:  Mariana M Clavé; Nair Y Maeda; Claudia R P Castro; Sergio P Bydlowski; Antonio A Lopes
Journal:  Pulm Circ       Date:  2017-08-25       Impact factor: 3.017

Review 6.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

7.  Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension.

Authors:  Vichaya Arunthari; Charles D Burger
Journal:  Open Respir Med J       Date:  2009-06-05

8.  Prothrombotic state in senile patients with acute exacerbations of chronic obstructive pulmonary disease combined with respiratory failure.

Authors:  Ya-Jun Song; Zhe-Hui Zhou; Yao-Kang Liu; Shi-Ming Rao; Ying-Jun Huang
Journal:  Exp Ther Med       Date:  2013-01-22       Impact factor: 2.447

9.  Updating clinical endpoint definitions.

Authors:  Paul M Hassoun; Sylvia Nikkho; Erika B Rosenzweig; Gail Moreschi; John Lawrence; John Teeter; Christian Meier; Ardeshir H Ghofrani; Omar Minai; Paula Rinaldi; Evangelos Michelakis; Ronald J Oudiz
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

10.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension.

Authors:  Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.